Loading…
← CockpitCompetitor Analysis › CERS Cerus CorporationOpen in the cockpit ↗

Cerus CorporationCERSCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum laggard 18
Mkt cap
$392M
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$5.87M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-35.9 pp
WACC 12.9%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$1.94
1D+2.1%
1W-8.5%
1M-16.0%
3M-30.5%
6M-27.9%
YTD-5.8%
1Y+26.8%
ATR %7.7%
Beta1.64
52w lowhigh44.1% off high

What Cerus does

Employees: 275

Cerus at a glance

Size Cerus (CERS) is a United States Health Care company (Medical Specialties) with a market value of $392M, the 2850th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.94 on 18 Nov 2026.

Performance Over six months the shares fell 27.9%, against -18.1% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 20 in its peer set.

Growth Revenue grew 13.7% over the last twelve months (peer median +14.7%); the operating margin is -12.2% (peer median 6.6%).

Valuation It trades at 1.8× enterprise value to sales against a peer median of 4.1× (8th cheapest of 21).

Capital Return on invested capital runs 35.9 points below its cost of capital (12.9% WACC).

Short interest Short interest is 7.2% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 83CERS 71
Six months, rebased to 100: Cerus against the median of its 20 peers (local-currency closes).

Cerus financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$227M$206M$180M$156M$162M
Revenue growth—+14%+15%-4%—
Gross profit$117M$110M$97.5M$84.0M$84.6M
EBITDA-$25.3M-$34.3M-$33.3M-$54.4M-$55.8M
Net income-$7.31M-$15.6M-$20.9M-$37.5M-$42.8M
Free cash flow$328,000$1.11M$8.52M-$47.8M-$27.6M
Capital expenditure$3.00M$3.73M$2.84M$4.60M$2.00M
Total debt$75.0M$96.9M$98.1M$96.0M$87.2M

Quarterly statements and history in the cockpit →

Cerus competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-40%-20%0%+20%4588700020226929MASS47363002386881330418306051866748BWAY301097CVSBS1609CERS6-month return →1-month return →
Up and to the right = strong over both horizons. Cerus is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×10×20×4588700020226929MASS3002386051866748BWAY9877301097CVSBSCERSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cerus is the large dot.

Cerus competitors and peer comparison

How Cerus compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cerus against its 20 peers (data as of 18 Nov 2026)
MeasureCERSPeer medianRank in peer set
1-month return-16.0%-10.9%8th lowest of 21
6-month return-27.9%-18.1%5th lowest of 20
Distance from 52-week high-44.1%-45.3%10th highest of 21
Revenue growth (TTM)+13.7%+14.7%10th lowest of 21
Operating margin-12.2%6.6%6th lowest of 21
EV / Sales1.8×4.1×8th cheapest of 21
ROIC minus cost of capital-35.9 pp-0.4 pp4th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Cerus CERSUnited States$392M-28%+14%-12%1.8×n/an/a
SEERS 458870.KSSouth Korea$392M-70%+174%37%5.5×-6.3%+247.0%
Shanghai Kehua Bio-Engineering 002022.SZChina$389M-14%+7%-40%1.7×n/an/a
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%1.0×-17.6%+15.4%
908 Devices MASSUnited States$396M+36%+14%-33%4.6×41.7%+15.9%
Taidoc Technology 4736.TWTaiwan$387M0%0%19%1.8×-9.5%-6.6%
Guanhao Biotech 300238.SZChina$397M-26%-12%3%7.1×n/an/a
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%1.4×n/an/a
InBody 041830.KSSouth Korea$380M-13%+22%22%1.4×-10.3%+16.9%
Shanghai General Healthy Information & Technology 605186.SSChina$379M-26%-11%5%7.8×n/an/a
Chison Medical Technologies 688358.SSChina$406M-27%-1%19%3.9×9.6%+5.6%
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%1.5×17.1%+18.1%
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%218.3×n/an/a
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%1.8×-4.2%-6.0%
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%4.8×24.9%+18.8%
Jenscare Scientific 9877.HKHong Kong$415M-32%+993%-106%17.8×n/an/a
Ningbo Tianyi Medical Appliance 301097.SZChina$418M-22%+46%8%4.4×n/an/a
CapsoVision CVUnited States$366M+5%+15%-213%24.8×n/an/a
Stratec SBS.DEGermany$365M+63%-6%4%1.8×19.1%+0.1%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%3.7×-13.1%+36.8%
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%4.2×5.7%+3.4%

Questions

Which companies are Cerus's closest peers?
The cockpit's peer set: SEERS (458870.KS), Shanghai Kehua Bio-Engineering (002022.SZ), OrbusNeich Medical (6929.HK), 908 Devices (MASS), Taidoc Technology (4736.TW), Guanhao Biotech (300238.SZ), Shanghai Titan Scientific (688133.SS), InBody (041830.KS).
Is Cerus expensive compared with its peers?
On ev / sales it trades at 1.8× against a peer median of 4.1×, 8th cheapest of 21 in its peer set.
How has Cerus stock performed?
Over six months to 18 Nov 2026 the shares returned -27.9% against -18.1% for the median peer; over one year +26.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.